Alek Safarian
InvestorCEO at ALSA Ventures
New York, New York, United States
FoundedVantage Biosciences
About
A pharmacist with over thirty years in drug development, Alek worked in regulatory and clinical research roles across the Asia-Pacific and founded the Sydney-based CRO Novotech. He holds a BPharm and MBA from the University of Sydney.
Experience
- ALSA VenturesCEOcurrent2018 β presentLondon Area, United Kingdom
- NovotechMember of the Board of Directors1996 β 2017
- NovotechCEO1996 β 2017
- Marion Merrell Dow (now Sanofi-Aventis)Head, Scientific Affairs, Asia-Pacific1990 β 1995
- Ciba-Geigy (now Novartis)Regulatory Affairs Associate1988 β 1990
Education
- University of SydneyMBA, Business Administration1993 β 1995
- University of SydneyB.Pharm., Pharmacy1984 β 1986
- St. Benedict's Grammar School1978 β 1982
Skills & more
+9 more
VaccinesGCPOncologySopSOPCTMSCROPharmaceutical IndustryStrategyLanguages Armenian Β· English
- University of Sydney Campaign Ambassador β University of Sydney
From Alek's professional profile.
Same school
Also attended University of Sydney210
+ 204 more
Shared employers
Also worked at Marion Merrell Dow (now Sanofi-Aventis)84
+ 78 more
Also worked at Ciba-Geigy (now Novartis)105
+ 99 more
Colleagues at ALSA Ventures
Network32
βΆ20 more connections
Barbara SchilbergBiao HeCharline GauthierClay WhiteheadCobih ObihCody AndersonDarius CheungDavis OkothDelia FlanaganDmytro DvurechenskyiDoug WilstermanEduardo ChadesEmily WangErik SchmidtEugene WeiFaisal AloufiiFrancesca BertocchiGilad NovickGladys NunezTerence Leahy
Investors connected to Alek in public investor directories β a warm-intro map.






)























